Please Note: Blog posts are not selected, edited or screened by Seeking Alpha editors.

Is long night over for CTT? Stock up 25% from recent bottom

|Includes: CTT, General Electric Company (GE), PHG, RTN

There is no getting around the fact that my first article on CTT was when the stock was trading at $2.17 late last year--when expectations were high that clinical study results and a ramp up of orders were pending. But it is obvious that these expectations were premature, and the stock price suffered accordingly. 

However, Competitive Technologies (NYSE Amex;CTT) recently announced the largest order in the company's history for its chronic pain management technology--100 unit order to Europe with 40 units shipped already. Also, the company's recent 10-Q revealed that the company bit the bullet and dismissed the exclusive distributor for the US for non-performance (reading between the lines). With the recent hiring of a National Sales Manager, it is clear that CTT has decided to take control over its direct sales and distributor network and not rely solely upon outside distributors.

The stock has been punished over the past few months, bounced off $1.25 and now is at $1.49. We would suggest that investors with an interest in medical device technology do some due diligence on this small company. CTT, with a market cap of only $17 million (11 million shares outstanding), has alot of room to the upside if the company's sales begin to ramp up quarter to quarter.  

Disclosure: Long CTT with recent purchases to average down.